Analyzing somatic and germline mutations and MSI may reveal clinically actionable mutations in a proportion of patients with advanced RCC.
A recent study in The Lancet Oncology suggests that the benefits of one tyrosine kinase inhibitor may extend to other subtypes of RCC.
Research presented at ASCO GU 2019 compared PFS with avelumab and axitinib vs sunitinib in patients with advanced renal cell carcinoma.
Incidental Primary Squamous Cell Carcinoma of the Kidney Within a Calyceal Diverticulum Associated With Nephrolithiasis
A 64-year-old man is diagnosed with primary squamous cell carcinoma within the upper pole calyceal diverticulum of the kidney. What are the best steps of management?
A study shows that microRNA depresses PLAG1, causing tumor growth in Wilms tumors.
Although the use of sorafenib in patients with treatment-naive metastatic renal cell carcinoma demonstrated clinical benefit, a phase IIb study did not support the use of dose escalation in these patients.
The combination of CB-839, a selective inhibitor of glutaminase, and everolimus seems to have disease activity in patients with advanced renal cell carcinoma.
Metastatic renal cell carcinoma (mRCC) patients who use non-aspirin NSAIDs have poorer overall survival than aspirin users and NSAID non-users, according to a new pooled retrospective analysis.
With a number of therapies now available for treatment of renal cell carcinoma, research is now ongoing to determine the best possible sequencing and potential combinations of those therapies.
The use of proton pump inhibitors does not appear to impact the efficacy of oral VEGF tyrosine kinase inhibitors in metastatic renal cell carcinoma, according to a new study.